
Opinion|Videos|June 15, 2024
REALISE Trial and Ruxolitinib Dosing Strategy
Author(s)Prithviraj Bose, MD
Dr. Bose discusses the REALISE trial and its implications for ruxolitinib dosing strategy, particularly in terms of safety and efficacy, and the purpose of this dosing strategy assessment in this patient population.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5































